Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line

Drug Metabolism and Disposition

Volumn 35, Issue 6, 2007, Pages 968-972

  Valentini, Alessandra ^a,d   Biancolella, Michela ^b   Amati, Francesca ^b   Gravina, Paolo ^a   Miano, Roberto ^b   Chillemi, Giovanni ^d   Farcomeni, Alessio ^d   Bueno, Susana ^d   Vespasiani, Giuseppe ^b   Desideri, Alessandro ^c   Federici, Giorgio ^a,e   Novelli, Giuseppe ^b   Bernardini, Sergio ^a,f  

^a University Hospital   (Italy)

^b Department of Biopathology and Diagnostic Imaging ^*  (Italy)

^c CASPUR   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; GLUCURONOSYLTRANSFERASE 2B11; GLUCURONOSYLTRANSFERASE 2B7; HISTONE DEACETYLASE INHIBITOR; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; VALPROIC ACID;

ARTICLE; CANCER GROWTH; CARCINOMA CELL; CELL DIFFERENTIATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UPREGULATION;

CELL DIFFERENTIATION; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; HISTONE DEACETYLASES; HUMANS; MALE; NEUROSECRETORY SYSTEMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOPYRUVATE HYDRATASE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; UP-REGULATION; VALPROIC ACID;

EID: 34249074258     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.014662     Document Type: Article

References (24)

1. Abrahamsson PA and Lilja H (1989) Partial characterization of thyroid-stimulating hormone-like peptide in neuroendocrine cells of the human prostate gland. Prostate 14:71-81.
2. Angelucci A, Valentini A, Millimaggi D, Gravina GL, Miano R, Dolo V, Vicentini C, Bologna M, Federici G, and Bernardini S (2006) Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways. Anticancer Drugs 17:1141-1150.
3. Baillie TL and Sheffels PR (1995) Valproate: chemistry and biotransformation, in Antiepileptic Drugs, 4th ed (Levy RH, Mattson RH, and Meldrum BS ed) pp 589-604. Raven Press, New York.
4. Bélanger A (2003) Inactivation of androgens by UDP-glucuronosyltransferases. Med Sci (Paris) 10:931-936.
5. Bélanger A, Pelletier G, Labrie F, Barbier O, and Chouinard S (2003) Inactivation of androgens by UDPglucoronosyltransferase enzymes in humans. Trends Endocrinol Metab 14:473-479.
6. Blaheta RA, Michaelis M, Driever PH, and Cinatl J Jr (2005) Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 4:383-397.
7. Chen G, Nomura M, Morinaga H, Matsubara E, Okabe T, Goto K, Yanase T, Zheng H, Lu J, and Nawata H (2005) Modulation of androgen receptor transactivation by FoxH1. A newly identified androgen receptor corepressor. J Biol Chem 280:36355-36363.
8. Chouinard S, Pelletier G, Bélanger A, and Barbier O (2006) Isoform-specific regulation of uridine diphosphate-glucuronosyltransferase 2B enzymes in the human prostate: differential consequences for androgen and bioactive lipid inactivation. Endocrinology 11:5431-5442.
9. Cox ME, Deeble PD, Lakhani S, and Parsons SJ (1999) Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res 59:3821-3830.
10. Culig Z, Steiner H, Bartsch G, and Hobisch A (2005) Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr-Relat Cancer 12:229-244.
11. Ethell BT, Andersoon AD, and Burchell B (2003) The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP- glucuronosyltransferases. Biochem Pharmacol 65:1441-1449.
12. Hsiao PW, Lin DL, Nakao R, and Chang C (1999) The linkage of Kennedy's neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator. J Biol Chem 274:20229-20234.
13. Hum DW, Bélanger A, Lévesque É, Barbier O, Beaulieu M, Albert C, Vallée M, Guillemette C, Tchernof A, Turgeon D, et al. (1999) Characterization of UDP-glucuronosyltransferases active on steroid hormones. J Steroid Biochem Mol Biol 69:413-423.
14. Hvamstad T, Jordal A, Hekmat N, Paus E, and Fossa SD (2003) Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol 44:215-221.
15. Jinawath N, Chamgramol Y, Furukawa Y, Obama K, Tsunoda T, Sripa B, Pairojkul C, and Nakamura Y (2006) Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology 44:1025-1038.
16. Lévesque É, Beaulieu M, Guillemette C, Hum DW, and Bélanger A (1998) Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line. Endocrinology 139:2375-2381.
17. Li P, Yu X, Ge K, Melamed J, Roeder RG, and Wang Z (2002) Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol 161:1467-1474.
18. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DeltaDeltaCT) method. Methods 25:402-408.
19. Minucci S and Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Rev 6:38-51.
20. Roth SY and Allis CD (1996) Histone acetylation and chromatin assembly: a single escort, multiple dances? Cell 87:5-8.
21. Thelen P, Schweyer S, Bernhard H, Wolfgang W, Florian S, and Ringert RH (2004) Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. Int J Oncol 24:25-31.
22. Turgeon D, Carrier JS, Lévesques É, Hum DW, and Bélanger A (2001) Relative Enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142:778-787.
23. Van der Laan MJ, Dudoit S, and Pollard KS (2004) Augmentation procedures for control of the generalized family-wise error rate and tail probabilities for the proportion of false positives. Stat Appl Genet Mol Biol 3:Article 15.
24. Xia Q, Sung J, Chowdhury W, Chen CL, Hoti N, Shabbeer S, Carducci M, and Rodriguez R (2006) Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 66:7237-7244.